Saudi Pharma renews 350 riyal facility from Saudi National Bank

Saudi Pharma has renewed a SAR 350 million credit facility with Saudi National Bank (SNB), marking a significant financial development for the company. The facility, which is Shariah-compliant, is intended to support the company’s operational and project financing needs, including the issuance of letters of credit and guarantees. The terms of the facility extend through 2027, aligning with similar recent agreements between SNB and other corporate clients, such as Perfect Presentation for Commercial Services Co. (2P), which renewed a SAR 200 million facility with the same maturity date.

The credit facility is secured by a promissory note for the full amount, ensuring financial stability and transparency in the arrangement. No related parties were involved in the transaction, according to the company’s disclosure. This move underscores SNB’s continued role as a key financial partner for major Saudi enterprises, particularly in the healthcare and commercial services sectors.

SNB has also recently extended its long-standing partnership with the Saudi Arabian Football Federation, reaffirming its commitment to supporting national development goals and Vision 2030. These developments highlight SNB’s broad role in both corporate finance and national initiatives.